Heraeus Medical has purchased the Synthecure product from Austin Medical Ventures. Distribution and commercial activities of the Synthecure product portfolio have already been transferred to Heraeus Medical.
Synthecure is a 100% synthetic calcium sulfate bone void filler that can be used directly at the site of infection in bone cavities and defects. It was developed by Austin Medical for optimal handling with established fast curing times, and an innovative kit design to best meet the needs of surgeons.
Currently, product sales are focused on the US market. Further information on the acquisition and its terms will not be disclosed.
With this acquisition, Heraeus Medical is continuing its global growth strategy by expanding its portfolio in the field of bioresorbables and infection management with the aim to meet the critical needs of today’s orthopedic patients. This milestone also represents a vertical portfolio expansion as it allows Heraeus Medical to gain access to new market segments within orthopedic trauma and foot & ankle surgery.
“We are happy to announce that Synthecure is now part of Heraeus Medical. The acquisition of Synthecure is a significant milestone in our strategy for business expansion. By integrating this innovative product into our existing product portfolio, we are underlining our commitment to provide high-quality products for excellent patient outcomes and driving growth in key therapeutic areas,” said Andrew Williamson, Heraeus Medical Co-President.
“Heraeus Medical’s complementary product portfolio and established reputation in the global market make it an ideal partner for Synthecure. Heraeus Medical is perfectly positioned to accelerate Synthecure’s future market expansion,” commented Brian Austin, CEO of Austin Medical Ventures.
Heraeus Medical has purchased the Synthecure product from Austin Medical Ventures. Distribution and commercial activities of the Synthecure product portfolio have already been transferred to Heraeus Medical.
Synthecure is a 100% synthetic calcium sulfate bone void filler that can be used directly at the site of infection in bone cavities and...
Heraeus Medical has purchased the Synthecure product from Austin Medical Ventures. Distribution and commercial activities of the Synthecure product portfolio have already been transferred to Heraeus Medical.
Synthecure is a 100% synthetic calcium sulfate bone void filler that can be used directly at the site of infection in bone cavities and defects. It was developed by Austin Medical for optimal handling with established fast curing times, and an innovative kit design to best meet the needs of surgeons.
Currently, product sales are focused on the US market. Further information on the acquisition and its terms will not be disclosed.
With this acquisition, Heraeus Medical is continuing its global growth strategy by expanding its portfolio in the field of bioresorbables and infection management with the aim to meet the critical needs of today’s orthopedic patients. This milestone also represents a vertical portfolio expansion as it allows Heraeus Medical to gain access to new market segments within orthopedic trauma and foot & ankle surgery.
“We are happy to announce that Synthecure is now part of Heraeus Medical. The acquisition of Synthecure is a significant milestone in our strategy for business expansion. By integrating this innovative product into our existing product portfolio, we are underlining our commitment to provide high-quality products for excellent patient outcomes and driving growth in key therapeutic areas,” said Andrew Williamson, Heraeus Medical Co-President.
“Heraeus Medical’s complementary product portfolio and established reputation in the global market make it an ideal partner for Synthecure. Heraeus Medical is perfectly positioned to accelerate Synthecure’s future market expansion,” commented Brian Austin, CEO of Austin Medical Ventures.
Copy to clipboard 
